MAGNA Pharmaceuticals, Inc.
Welcome, we're excited to share our patented WoundGelHA!
Hi, we are MAGNA Pharmaceuticals! We are excited to introduce you to our patented WoundGelHA (WGHA)! WGHA is formulated to provide wound care dressing & management. WGHA is a combination of emollients & sodium hyaluronate, which function to maintain tissue hydration & support the healing process. WGHA has been demonstrated to be of value in the management of certain skin ulcers. Sodium hyaluronate is a salt of hyaluronic acid, a naturally occurring molecule found in various body tissues. The sodium hyaluronate present in WGHA is derived from synthetic sources. WGHA [(based on FDA 510(k) K143527)] is indicated for management of exudating wounds such as leg ulcers, pressure ulcers, diabetic ulcers, surgical wounds (post-operative incisions and donor cites), mechanically or surgically debrided wounds, and for second degree burns. WGHA should be applied after the ulcer/wound is cleaned with normal saline solution. Excess moisture should be remoced using dry gauze. WGHA is applied liberally into the ulcer/wound & surrounding area. A non-stick gauze should then be applied and covered with an occlusive dressing.